- Active not recruitingPHASE1, PHASE2
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
This study is testing a new treatment, LY3884961, for babies with a serious inherited condition called Type 2 Gaucher disease. Researchers want to see if it's safe and effective. It's a long-term study, following babies for up to 5 years.
For: Gaucher Disease, Type 2United States · United Kingdom - RecruitingPHASE1, PHASE2
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
This study is testing a new medicine, LY3884961, for adults with Gaucher disease, type 1. It aims to find the right dose and see how safe and effective it is for symptoms affecting the body, but not the brain.
For: Gaucher Disease · Gaucher Disease, Type 1United States · Australia · Brazil